Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after market close. Here’s what you need to know.

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.

DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.

The market awaits DexCom's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to u ...

Dexcom (($DXCM)) announced an update on their ongoing clinical study. Study Overview: The COMPASS Program, officially titled ‘Continuous ...

The AI health companion unifies data from wearables and habits across sleep, fitness, and nutrition into personalized ...

The market awaits ResMed's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to u ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of DexCom, Inc. (NASDAQ: DXCM) s ...